drugset / Trial / NCT01926977

Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration

NCT01926977

Phase 1/2 Completed 100 enrolled Arshad Khanani Genentech, Inc. · collab
Non-randomizedParallel-groupSingle-blindTreatment

Summary

This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of Ranibizumab vs Aflibercept.

Timeline

Start
2013-09
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aflibercept Protein / enzyme biologic 2 mg Intravitreal
Comparator Ranibizumab Monoclonal antibody 0.5 mg Intravitreal